Clearbridge Health

Clearbridge Health FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Clearbridge Health (1H3.SI) as of Sep 27, 2026 is 58.34 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 12.80 % — a change of 355.74% (higher).

FCF Conversion

58.34 %

YoY

355.74%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Clearbridge Health is 2026 58.34 % . FCF Conversion Rate (FCF/EBITDA) of Clearbridge Health was 2025 12.80 % . It decreases by 355.74% higher compared to the previous year.

The Clearbridge Health FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2017
126.13 SGD
Jan 1, 2018
64.45 SGD
Jan 1, 2019
97.88 SGD
Jan 1, 2020
248.62 SGD
Jan 1, 2021
19.16 SGD
Jan 1, 2022
23.91 SGD
Jan 1, 2023
12.80 SGD
Jan 1, 2024
58.34 SGD
The Clearbridge Health FCF Conversion history
YEARFCF ConversionYoY
58.34 %+355.74%
12.80 %-46.47%
23.91 %+24.82%
19.16 %-92.29%
248.62 %+153.99%
97.88 %+51.89%
64.45 %-48.91%
126.13 %-67.30%
385.76 %-531.73%
-89.35 %+44.69%
-61.75 %—
Access this data via the Eulerpool API

Clearbridge Health Stock analysis

What does Clearbridge Health do? Clearbridge Health Ltd is an international company in the healthcare and diagnostics sector based in Singapore. The company was founded in 2017 and focuses on the use of innovative technology, information, and communication systems to provide efficient and precise diagnostics and medical care. The business model of Clearbridge Health is based on a wide range of services and products, divided into three segments: Clinical diagnostics, healthcare services, and digitization. These divisions are interconnected and allow the company to offer a comprehensive range of healthcare services. In the field of clinical diagnostics, the company offers a variety of laboratory and radiology services. Clearbridge Health has a strong presence in Singapore and Indonesia, where it has several diagnostic laboratories specializing in areas such as pathology, microbiology, genetics, and molecular diagnostics. In addition, the company has partnerships with leading diagnostic laboratories worldwide to provide its customers with an even broader range of diagnostic options. In the healthcare services segment, Clearbridge Health offers a wide range of services including diagnosis, treatment, and disease prevention, as well as health management. A key focus in this area is the care of cancer patients. Here, the company has developed a unique self-financing model where it invests in diagnosis and treatment and benefits from the outcomes achieved. The goal is to provide cancer patients with fast diagnosis and comprehensive, personalized treatment. Clearbridge Health has partnerships with leading cancer centers worldwide and utilizes the latest technologies to enable fast and accurate diagnosis. In the digitization segment, Clearbridge Health offers innovative technology solutions to digitalize the healthcare sector and improve efficiency in healthcare delivery. One of the products includes a cloud-based platform for medical imaging called teleradiology. The platform allows for the digital transmission of images from one location to another, saving time and costs and improving efficiency in patient diagnosis and treatment. Clearbridge Health has experienced rapid growth in recent years. The company has expanded its presence in Asia and other parts of the world and continues to pursue an ambitious expansion strategy. The goal is to become a global leader in healthcare and diagnostics. In summary, Clearbridge Health is an innovative company in the healthcare and diagnostics sector that offers a wide range of services and products. The company has a strong presence in Asia and collaborates closely with leading diagnostic laboratories and cancer centers worldwide. Clearbridge Health is committed to improving healthcare delivery and promoting the adoption of innovative technology solutions to enhance efficiency. The company has experienced impressive growth in recent years and continues to pursue an ambitious expansion strategy. Clearbridge Health is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Clearbridge Health stock

FCF Conversion Rate (FCF/EBITDA) of Clearbridge Health is 58.34 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Clearbridge Health changed from 12.80 % to 58.34 %, representing a 355.74% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Clearbridge Health since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Clearbridge Health with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — Clearbridge Health

All Key Metrics — Clearbridge Health